NorUDCA (24-nor-ursodeoxycholic acid) is a chemically modified bile acid that has already shown promising results in the treatment of liver diseases such as primary sclerosing cholangitis (PSC) and is being tested in clinical studies. As PSC is often associated and potentially causally linked with chronic inflammatory bowel disease, a MedUni Vienna research team, jointly led […]
Focus on the gut-liver axis
